This study assessed the possibility to build a prognosis predictor, based on microarray gene expression measures, in stage II and III colon cancer patients. Tumour (T) and non-neoplastic mucosa (NM) mRNA samples from 18 patients (nine with a recurrence, nine with no recurrence) were profiled using the Affymetrix HGU133A GeneChip. The k-nearest neighbour method was used for prognosis prediction using T and NM gene expression measures. Six-fold cross-validation was applied to select the number of neighbours and the number of informative genes to include in the predictors. Based on this information, one T-based and one NM-based predictor were proposed and their accuracies were estimated by double crossvalidation. In six-fold cross-validation, the lowest numbers of informative genes giving the lowest numbers of false predictions (two out of 18) were 30 and 70 with the T and NM gene expression measures, respectively. A 30-gene T-based predictor and a 70-gene NM-based predictor were then built, with estimated accuracies of 78 and 83%, respectively. This study suggests that one can build an accurate prognosis predictor for stage II and III colon cancer patients, based on gene expression measures, and one can use either tumour or non-neoplastic mucosa for this purpose.
Introduction
Postoperative treatment of stages II and III colon cancer patients remains a highly debated field. For stage II patients, the question of whether adjuvant chemotherapy should be given or not is still unanswered. A benefit of adjuvant chemotherapy is suggested by most metaanalyses but it has never been proved with statistical significance (Benson et al., 2004) . The reason is probably the lack of power of the studies; if existing, the benefits of adjuvant chemotherapy are probably minor and, thus, a study would need to enroll thousands of patients to establish statistical significance. However, if such a study would show a benefit of adjuvant chemotherapy in stage II patients, it may not be logical to conclude that this treatment should be given to all patients, given that 75% are cured by surgery alone (IMPACT B2, 1999) .
The problem for stage III patients is somewhat different. The usefulness of adjuvant chemotherapy has been clearly demonstrated more than 10 years ago (Moertel et al., 1990) , but the 'standard' treatment, consisting of a 6-month fluorouracil (FU)-based therapy, has been recently questioned (Andre et al., 2004) . In the study of Andre et al. (2004) , adding oxaliplatin to the 'standard' therapy was shown to improve the 3-year disease-free survival from 73 to 79%. However, even if this improvement in survival rates is confirmed based on 5-year follow-up, it may not be logical to conclude that the 'new standard' adjuvant chemotherapy should include oxaliplatin, given its neurotoxicity (Cersosimo, 2005) . This would lead to administering to all patients oxaliplatin that would be useful for only a few.
In fact, the situation is quite similar for both disease stages and includes a cost-benefit problem. Compared to the 'standard' treatment (observation in stage II patients, FU-based therapy in stage III patients), a 'more aggressive' treatment (adjuvant chemotherapy in stage II patients, oxaliplatin in stage III patients) probably benefits only a minority of patients, while it has no advantages or is potentially harmful for the vast majority. The situation would be radically different if new and accurate prognosis factors could be identified. Being able to isolate a subgroup of patients with a high risk or recurrence would permit more rational designs of clinical studies assessing 'standard' versus 'more aggressive' treatment: instead of including all patients of a given group, these studies could only include patients with a high risk of recurrence, thus more likely to benefit from 'more aggressive' treatment. Such an approach would increase power to demonstrate a statistical significance between treatments and would address the cost-benefit problem.
Microarray gene expression profiling has been reported to accurately predict the prognosis of several malignant tumours (breast carcinomas Van't Veer et al., 2002) , lung carcinomas (Bhattacharjee et al., 2001; Beer et al., 2002) , lymphomas (Rosenwald et al., 2002; Shipp et al., 2002) ). Thus, by analogy with these tumours, it may be postulated that gene expression profiling represents a valuable tool in predicting the prognosis of stage II and III colon cancer patients and thereby in identifying a subgroup of patients at high risk of recurrence. Microarray gene expression studies in colorectal cancer have so far shown the possibility to distinguish between normal and tumour tissue samples, between different stages of disease, and between different tumour locations (leftsided versus right-sided) (Alon et al., 1999; Backert et al., 1999; Hedge et al., 2001; Kitahara et al., 2001; Notterman et al., 2001; Agrawal et al., 2002; Birkenkamp-Demtroder et al., 2002; Iacopetta, 2002; Lin et al., 2002; Zou et al., 2002; Fredericksen et al., 2003; Tureci et al., 2003; Williams et al., 2003; Bertucci et al., 2004) . The issue of prognosis was only recently addressed, with promising results (Bertucci et al., 2004; Wang et al., 2004) .
The present study aimed to assess the possibility to build a prognosis predictor for both stage II and III colon cancer patients, based on microarray gene expression measures. In contrast to the two aformentioned studies, non-neoplastic mucosa (NM), as well as tumour (T), gene expression profiles were considered.
Results

Selection of prognosis predictor parameters
For each data set (T and NM), a total of 150 prognosis predictors (50 possible values for the number m of informative genes, three possible values for the number k of nearest neighbours) were considered and their performance assessed using six-fold cross-validation. The distributions of the numbers of false predictions obtained with each of these 150 predictors are given in Figure 1 . Results were quite similar for NM-and T-based predictors: no pair of parameters (m, k) allowed a perfect concordance between the predicted and the observed evolutions; the numbers of false predictions ranged between two and four; two false predictions (out of 18, accuracy ¼ 89%) represented the most frequent result (108 out of 150 predictors, 72%, with NM; 84 out of 150 predictors, 56%, with T). Figure 2 shows the numbers of false predictions as a function of both parameters m and k. With the NM data set, predictors built with 65 or fewer informative genes yielded three and four false predictions; predictors built with more than 70 informative genes yielded stable results (two false predictions); the lowest number of informative genes giving the lowest number of false predictions (two out of 18) was m ¼ 70 (with k ¼ 3 neighbours). With the T data set, predictors built with 25 or fewer informative genes yielded three false predictions, whatever the number of nearest neighbours; predictors built with more than 30 informative genes yielded two false predictions with k ¼ 3 and 5 neighbours, and three or four false predictions with k ¼ 1 neighbour; the lowest number of informative genes giving the lowest number of false predictions (two out of 18) was m ¼ 30 (with k ¼ 3 neighbours). 
Proposition of a prognosis predictor
Based on the results of the six-fold cross-validation, two prognosis predictors were proposed. The first predictor, based on the NM expression profiles of all 18 patients, was built by selecting the 70 genes with largest absolute t-statistics. Of these genes, 35 were overexpressed in patients who developed a recurrence, while the other 35
were overexpressed in patients who remained diseasefree for at least 5 years. Both lists of genes are given in Table 1 . Informative genes can be divided into three categories:
(1) Plasma membrane receptors (guanine nucleotide binding protein, lysosomal-associated membrane protein, tumor necrosis factor superfamily member 6, Similarly, to build the T-based predictor, informative genes were selected using all 18 patients, by taking the 30 genes with the largest absolute t-statistics. Of these genes, 16 were overexpressed in patients who developed a recurrence, while the other 14 were overexpressed in patients who remained disease-free for at least 5 years. Both lists of genes are given in Table 2 . Genes overexpressed in the tumours of patients who recurred coded for proteins involved in nucleic acid and protein metabolism (a member of COP9 family, member Z of H2A histone family, SRB7 suppressor of RNA polymerase B, v-yes-1, stress 70 protein chaperone, CDC28 protein kinase regulatory subunit 1B, dynactin 3, DnaJ/ Hsp40 homolog, mitochondrial ribosomal protein L24, APG12). Also overexpressed in the tumours of patients who recurred were genes coding for proteins of the extracellular matrix (e.g. matrix metalloproteinase 12), and proteins of the immune response (e.g. interleukin 8).
Estimation of the generalization error of the prognosis predictor
The results of the double cross-validation are summarized in Table 3 (Non-neoplastic mucosa) and Table 4 (Tumour). In both tables, each row gives the results of one of the three steps of the 'outer level' crossvalidation. For each step, 12 samples were used as the learning set, while the other six were used as the test set.
In both tables, the first set of columns indicates the distribution of the numbers of false predictions (out of 12) obtained with each of the 150 predictors in the 'inner level' cross-validation based on the 12 patients of the learning set. The second column gives the lowest numbers of informative genes and nearest neighbours that yielded the lowest number of false predictions for the 'inner level' cross-validation (six-fold cross-validation). These parameter values were used to build the prognosis predictor based on the learning set of size 12. This predictor was then applied to assign a prognosis to each of the six patients of the test set. The false prediction rates, obtained for each of the three steps, are given in the third column. The average of these three false prediction rates provides an estimate of the generalization error of the predictors. The estimate of the generalization error was 17% for the 70-gene NMbased predictor, and 22% for the 30-gene T-based predictor. Thus, the estimated accuracy of these two predictors was 83 and 78%, respectively.
Discussion
The aim of the present study was to build a prognosis predictor that could be used, for both stage II and stage III colon cancer, to identify patients at high risk of ADP-ribosylarginine hydrolase NM_001125 Table 3 Results of the double cross-validation (Non-neoplastic mucosa)
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recurrence and thus more likely to benefit from a more aggressive postoperative treatment. The statistical analysis was therefore performed on the combined sample of stage II and III patients but did not include any subanalyses by stage of disease due to the small sample size. Patients were homogeneous with regard to the postoperative treatment, as they all received the current 'standard' treatment: none of the 10 stage II patients received any adjuvant chemotherapy, while all eight stage III patients received a 6-month FU-based adjuvant chemotherapy. With this 'standard' treatment, nine patients remained disease-free for at least 5 years and nine developed a metastatic recurrence. The latter type of patients is of interest as it represents individuals who may potentially have benefited from a more aggressive treatment. Note that a pooled analysis allows us to draw a common conclusion for stage II and III patients, but does not allow any separate conclusions for either group.
Studies aiming to propose a predictor, for either diagnosis or prognosis purposes, are usually designed as follows: samples are split into a training set and a validation set; informative genes and possibly other prediction parameters are selected based on the training set, using some arbitrary rule; the resulting predictor is assessed on the validation set. The design of the present study, which includes two distinct rounds of crossvalidation with different aims, deserves further discussion. The first part concerns the selection of a predictor, while the second aims to estimate the generalization error of the selected predictor. The k-nearest neighbour classifier was chosen because it has been shown to be competitive with more complex approaches, such as aggregated classification trees and support vector machines Dudoit and Fridlyand, 2003) . The main parameters of this classifier, namely the numbers of informative genes m and nearest neighbours k, were not chosen a priori but using cross-validation in the first part of the study.
For both types of predictors (NM and T based), 150 different pairs of parameters were considered and the performance of the corresponding predictors was assessed using six-fold cross-validation. While this first part mainly aimed to select the predictor parameters, it also yielded information about the stability of NM-and T-based prognosis predictors, that is, the sensitivity of prediction error to the parameters (m, k).
Based on results of the first cross-validation, two prognosis predictors (a 30-gene T-based predictor and a 70-gene NM-based predictor) were built on the whole set of patients. When proposing a predictor, it is important to provide an estimate of its accuracy. As a second set of independent samples was not available, a double cross-validation design was used, with an 'inner level' six-fold cross-validation for parameter selection and an 'outer level' three-fold cross-validation for performance assessment of the selected predictor. In order to obtain an honest estimate of generalization error, it is crucial that all aspects of predictor selection be included in the cross-validation process. Thus, for each of the three steps of the 'outer level' crossvalidation, we reproduced exactly what had been done in the first part of the study with an 'inner level' crossvalidation: (i) selection of the parameters (m, k) yielding the best results by six-fold cross-validation, (ii) use of this information to build a predictor based on the 12 learning set patients. Note that the estimate of the generalization error, obtained by averaging the error estimates of the 'outer level' cross-validation, should be conservative, since it is computed based on sets of 12 patients (instead of 18). This suggests that the accuracy of the proposed predictors is not overestimated.
The results of the present study clearly suggest the possibility to build an accurate prognosis predictor for both stage II and III colon cancer patients based on microarray gene expression measures. This first conclusion supports the findings of two previous reports, even though different colon cancer subtypes were considered. The study of Bertucci et al. (2004) , which comprised all stages of disease, identified a gene set that separated patients with significantly different 5-year survival and suggested the relative closeness of T gene expression profiles in patients with synchronous metastases and in those with metachronous metastases. The study of Wang et al. (2004) , which focussed on stage II colon cancer, identified a 23-gene signature that predicted prognosis with 78% accuracy (the same accuracy as that of our 30-gene T-based predictor). Thus, it appears more and more likely that microarray gene expression profiling will prove to be a valuable tool to predict the prognosis of colon cancer patients, as previously suggested for other types of cancer (Bhattacharjee et al., 2001; Beer et al., 2002; Rosenwald et al., 2002; Shipp et al., 2002; Van't Veer et al., 2002) .
The main finding of our study is the possibility to build a prognosis predictor based on either T or NM gene expression profiles. To our knowledge, the issue of profiling the non-neoplastic tissue distant from the tumour for prognosis purpose has never been addressed before, neither for colorectal cancer nor for other types of solid tumours. The idea of studying the nonneoplastic mucosa was suggested by a growing evidence that phenomena in cancer are not confined to tumour cells but also involve adjacent cells. There is an increasing evidence that interactions between stromal and cancer cells are a prerequisite for metastases to occur (Mueller and Fusenig, 2004) . However, it remains unclear whether this metastatic potential originates in cancer cells and/or in stromal compartments. Metastatic potential may be present from the origin of the tumour (Bernards and Weinberg, 2002; Ramaswamy et al., 2003) . Hence, non-neoplastic mucosa on which the tumour has arisen may contain some helpful information. This hypothesis is supported by a recent study in which several genes involved in human colon cancer were shown to have an altered expression in the morphologically normal colonic mucosa (Chen et al., 2004) .
The question of whether one should build a prognosis predictor based on T or NM gene expression profiles immediately arises. The estimated accuracy of the 70-gene NM-based predictor was greater than that of the 30-gene T-based predictor (83 versus 78%). However, given the limited sample size, this difference is not sufficient to conclude to the superiority of the nonneoplastic mucosa. Useful information can be drawn from the cross-validation selection part of the study regarding the stability of both predictors, that is, their sensitivity to changes in parameter values. At first sight, results observed with both predictors may appear equivalent: the range of false predictions was the same (2-4) and the percentages of predictors yielding two or three false predictions were very close (95 and 98% for NM-and T-based predictors, respectively). However, when considering the distribution of the numbers of false predictions as a function of the numbers of informative genes m and neighbours k, the T and NM predictors exhibit a different behaviour. With NMbased predictors, three and four false predictions were only observed with predictors built with fewer than 65 informative genes; with predictors built with 70 or more informative genes, error rates seemed to stabilize, that is, they were not influenced by changes in either the number of genes m or the number of neighbours k. A similar zone of stability was not observed with T-based predictors. With k ¼ 1 nearest neighbour, the numbers of false predictions varied with the number of informative genes; likewise, for a given number of informative genes, error rates were influenced by the number of nearest neighbours. This higher stability of NM-based predictors represents an argument in favour of their use. NM samples are homogeneous while T samples include both cancer and stromal cells. Thus, it is possible that differences in stability between the two types of predictors simply reflect this difference in tissue homogeneity. In the present study, laser-capture microdissection was not used. This technique could have possibly yielded more stable results for T-based predictors. However, laser-capture microdissection cannot be considered as a routine technique, for reasons of cost, time, and technical difficulties. Hence, in addition to their possibly higher accuracy, NM-based predictors have practical advantages over T-based predictors.
There is a growing evidence that the tumour microenvironment, largely orchestrated by inflammatory cells, is involved in the neoplastic process, fostering cell proliferation, survival and migration (Mueller and Fusenig, 2004) . Genetic or gene expression changes could occur without altering the DNA sequence and explain how stromal cells escape the normally growthinhibitory effects and become willing partners in enhancing epithelial tumour progression. Accordingly, we have observed in tumour samples of patients who have developed a recurrence the overexpression of stromal cell genes previously reported to play a major role in the tumour migration (e.g. matrix metalloproteinase 12 and interleukin 8). The overexpression of members of these gene families has been observed in the few gene expression profile studies that have directly addressed the issue of prognosis (Bertucci et al., 2004; Wang et al., 2004) . These genes play a particularly crucial role in carcinogenesis, since an increased expression in the mammary gland of the extracellular matrixdegrading enzyme, matrix metalloproteinase-3, has been shown to be sufficient to induce mammary tumours (Sternlicht et al., 1999) . As in previous gene expression studies on colon tumours (Alon et al., 1999; Kitahara et al., 2001; Birkenkamp-Demtroder et al., 2002; Lin et al., 2002; Bertucci et al., 2004) , a significant change in the expression of gene families coding for proteins involved in general metabolism, cell cycle, apoptosis, adhesion, cytoskeleton, signal transduction, transcription, translation, RNA and protein processing, immune systems and others has been observed.
The potential usefulness of the non-neoplastic mucosa in predicting the prognosis of stage II and III colon cancer patients is somewhat surprising and difficult to understand with the current biological knowledge. It should not be referred to the 'microenvironment theory' to explain it, since this concept involves nontumoral cells that are very close to tumoral cells. In the present study, non-neoplastic tissue samples that were profiled were distant (more than 5 cm) from the gross tumour limit. A few hypotheses are possible in view of genes that were found to be differentially expressed. These included genes coding for proteins involved in inflammation and tumour cell invasion. Numerous genes involved in signalling pathways were also found to be overexpressed in the non-neoplastic mucosa of patients who remained disease-free and who recurred, suggesting the possibility of a cross-talk between 'normal' cells distant from the tumour and tumoral cells. Indeed, these genes included some coding for membrane receptors (e.g. tumor necrosis factor receptor 6 (TNFR6), prostanglandin E receptor 2, interleukin 1 receptor (IL1R)) and others coding for proteins involved in signalling cascades (most of them involved in the MAPK, Jak-STAT and Wnt signalling pathways). The role of these signalling pathways has been previously reported in other studies of gene expression in colorectal tumours Bertucci et al., 2004) . Of interest is the overexpression of IGF-1, the major mediator of growth hormone, shown to perform multiple functions in the growth and proliferation of colorectal cancer (Durai et al., 2005) . Recently, IGF-1 has been involved as a chemotactic factor in tumour invasiveness and mainly in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis (Bustin et al., 2002; Jiang et al., 2003) . Thus, the cross-talk, previously shown between stromal and cancer cells, could be relayed in the non-neoplastic mucosa far from the primary tumour. Similarly, the concept that inflammation is a crucial component of tumour progression could play a major role from afar the tumour. Indeed, the overexpression of membrane receptors such as TNFR6, prostanglandin E receptor 2, and IL1R supports this hypothesis. As also expected, an overexpression of genes coding for proteins implicated in immune surveillance has been found. Thus, our results favour a view in which the apparently normal tissue in which a tumour appears and develops may contain or acquire information on the ability of this tumour to further invade and disseminate. The control exerted by nontumoral tissue on neoplastic lesion formation may be part of the homeostatic tissue functions that may be either genetically 'weak' or altered by continuous chemical or inflammatory aggressions.
In conclusion, the present study suggests the possibility to build an accurate prognosis predictor using gene expression profiles for stage II and III colon cancer patients. More remarkably, it suggests that such a predictor may be based on either the NM or the T gene expression profiles. The study also raises questions regarding the role of the 'normal mucosa' distant from the tumour. But this study has to be confirmed by larger other studies.
Materials and methods
Patients and samples
In total, 18 patients operated on for a colonic adenocarcinoma in the Department of Digestive Surgery of the Hospital Tenon between 1995 and 1998 were included in this study. Main patient and tumour characteristics are given in Table 5 . There were eight women and 10 men, with a mean age of 71 years (extremes: 39-87). None of these 18 patients had distant metastasis at the time of surgery. A total of 10 patients had no lymph node metastasis (stage II) and did not receive any chemotherapy. The other eight patients had lymph node metastasis (stage III) and received a 6-month adjuvant chemotherapy, with FU and levamisole. Patients were evaluated at 3-month intervals for the first postoperative year and at 6-month intervals thereafter. Metastatic reccurrences were identified by clinical examination, completed by chest X-ray and liver ultrasound (or CT scan). Nine of the 18 patients (five stage II patients and four stage III patients) developed a distant metastasis in the follow-up, with a mean time of diagnosis of 29 months (extremes: 14 and 53 months). The other nine patients remained disease-free for at least 60 months (mean duration of follow-up: 75 months; extremes: 64 and 98 months).
For each patient, tumour and adjacent non-neoplastic colon tissue samples were collected at the time of surgery, with patients' informed consent, and were stored in liquid nitrogen within 0.5 h after the resection. Non-neoplastic tissue samples were collected at a distance greater than 5 cm from the gross tumour limit with a careful dissection of the mucosa from the deeper layers. Samples were reviewed by a pathologist to check the absence of tumour cells in NM samples and the presence of at least 80% tumour cells in tumour samples. The 18 tumours did not exhibit microsatellite instability as assessed using the five microsatellites markers (BAT25, BAT26, D5S346, D2S123 and D17S250) defined as reference panel and two additional markers (BAT40 and D13S153) defined as alternative loci by the international workshop on microsatellite instability and RER phenotype in cancer detection and familial predisposition (Boland et al., 1998) .
Total RNA was extracted from the 36 samples (18 tumour and 18 NM samples) using Trizol reagent. Targets were hybridized to Affymetrix HGU133A GeneChips, containing a total of 22 283 probe-sets (Affymetrix, Santa Clara, CA, USA), as described in the Affymetrix GeneChip Expression Analysis Manual (Affymetrix, Wooburn Green, UK). Briefly, 5 mg (100 ng/ml) of total RNA was used to synthesize doublestranded cDNA with SuperScript II reverse transcriptase (Invitrogen, Cergy Pontoise, France) and a T7-(dT)24 primer (Proligo Biochemie GmbH, Hamburg, Germany). Then, biotinylated cRNA was synthesized from the double-stranded cDNA using the RNA Transcript Labelling kit (Enzo Life Sciences, Farmingdale, NY, USA) and was purified and fragmented. The fragmented cRNA was hybridized to the oligonucleotide microarrays, which were washed and stained with streptavidin-phycoerythrin. Scanning was performed with a GeneArray Scanner Update (Affymetrix, Wooburn Green, UK).
Statistical methods
Preprocessing Starting from the 36 CEL files, gene expression measures were computed using the Robust Multichip Average (RMA) method described in Irizarry et al. (2003) and implemented in the Bioconductor R package affy. This method includes the following successive steps: (1) backgroung correction; (2) probe-level quantile normalization; (3) Calculation of expression measures using median polish.
Two genes Â patients matrices of expression measures were constituted including, respectively, for each patient the gene expression measures in tumour samples and the gene expression measures in NM samples. In the remainder of the article, we refer to the resulting two data sets as T and NM, respectively.
Prognosis prediction The prognosis prediction method consists of the following two steps.
(a) Selection of informative genes. Genes that are differentially expressed between patients who experienced a tumour relapse and patients who remained disease-free are identified based on two-sample t-statistics with equal variance. The m genes with the largest absolute t-statistics are retained to build a prognosis predictor. (b) Prognosis prediction. The k-nearest neighbour method, based on the Euclidean distance between the expression profiles for the m informative genes of step (a), is applied to predict prognosis. Specifically, the prognosis of a given patient is predicted as the most common prognosis among its k nearest neighbours, that is, the k patients with the closest expression profiles.
Selection of prognosis predictor parameters For each data set (T and NM), six-fold cross-validation was used to select the two prognosis predictor parameters, namely the number of informative genes m and the number of nearest neighbours k.
A total of 150 prognosis predictors were considered, corresponding to the following parameter values: k ¼ 1, 3, and 5, Colon cancer prognosis by gene expression profiling A Barrier et al and m ¼ 5, 10,y, 250. The performance of a given prognosis predictor, indexed by the pair (m,k), was assessed as follows. The 18 samples were divided into six sets of three samples. Each of these six sets was used in turn as the validation set; the prognosis predictor was built using the training set formed by the remaining 15 samples and used to assign a prognosis (recurrence or no recurrence) to the three validation samples; the predicted prognoses were then compared to the actual recurrence status; the numbers of false predictions (discordance between the predicted and actual evolutions) and true predictions were recorded for each of the 18 samples. Thus, for each of the 150 prognosis predictors, that is, each (m,k) pair, a prediction error rate (out of 18) was obtained.
Proposition of a prognosis predictor For each data set (T and NM), because of ties in the error rates in six-fold crossvalidation, the number of informative genes of the proposed predictor was set to be the lowest number of informative genes, giving the lowest number of false predictions. Selection of informative genes was based on all 18 samples.
Estimation of the generalization error of the prognosis predictor A double or nested cross-validation scheme was used to assess the performance of the proposed T and NM prognosis predictors. For the 'outer level' of cross-validation, the 18 samples were divided into three sets of six samples (three-fold cross-validation). Each of these three sets was used in turn as the test set, the other two sets (12 patients) being used as the learning set. For each of the three steps in the 'outer level' cross-validation, prognosis predictors (one for each data set) were built based on the learning samples using the previously described method: (i) determination of the lowest number of genes and the lowest number of nearest neighbours giving the lowest number of false predictions (out of 12), using six-fold cross-validation ('inner level' of cross-validation); (ii) selection of the m informative genes based on the 12 patients. The prognosis predictors were used to assign a prognosis to the six test samples. The predicted prognoses were then compared to the actual recurrence status, giving a false prediction rate (out of six). The three false prediction rates (one for each of the three steps of the 'outer level' cross-validation) were averaged to provide an estimate of the generalization error.
Software The statistical analysis was performed with the open-source software R, Version 2.0.1 (http://cran.r-project/ org), and Bioconductor packages (www.bioconductor.org). The following R packages were used: affy Version 1.5.8 (Irizarry RA, Gautier L, Bolstad BM, Miller C), annaffy Version 1.0.11 (Smith CA), class Version 7.2.11 (Venables T, Ripley B, Hornik K, Gebhardt A), hgu133a Version 1.6.5 (Zhang J) and multtest Version 1.5.2 (Pollard KS, Ge Y, Dudoit S).
